Mergers and acquisitions (M&A) 
are relatively common in the Life
Sciences industry. Some years ago,
companies had a heightened M&A
period. As larger companies looked to
expand and realign their portfolios and
offset losses from expiring patents, the
acquisition of smaller firms with
discovery and innovation experience
proved to be the optimal path.

Today we see deals move away from M&A 
to collaboration and partnership agreements.
These deals take shape in a variety of forms.
One such form is the high-profile collaboration
of big pharma and small companies such as the Pfizer and BioNTech collaboration.
This led to the vaccine for COVID-19 and moved
further into collaborations with government,
outsourced development and manufacturing 
to meet strategic goals. 

While your company’s motivating
reasons to explore collaboration may
shift over time, the drive to remain
competitive will be a part of every deal
you make. With that comes the
complexities of rights and royalties,
pricing and contract management

Collaboration model exchanges